SEATTLE, July 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) today announced that Dr. Jay Umbreit has joined the Clinical Department as the new Medical Director of the XYOTAX/CT-2103 program.
XYOTAX is a chemotherapeutic drug candidate for treating lung and ovarian cancers in women. Specifically, Dr. Umbreit will take over the lead on the PGT307 trial, and be the medical lead on the PIONEER report.
Scott Stromatt, CTI's EVP, Clinical Development and Regulatory Affairs, said, "Dr. Umbreit has joined CTI to head our Xyotax development program. We are pleased to have Dr. Umbreit join our team and to bring his many years of experience to CTI."
Dr. Umbreit comes to CTI most recently from PPD, a global contract research organization where he developed pharmaceutical products. Previously, Dr. Umbreit was a professor of medicine at both the University of South Alabama and Emory University in Atlanta, specializing in Hematology and Oncology. He also did basic research at the University of South Alabama supported by National Institutes of Health, National Institute of Diabetes Digestive and Kidney Disease (NIDDKD). He also conducted clinical research at University of South Alabama supported by National Institutes of Health, at Emory supported by Eastern Cooperative Oncology Group, and at PPD. Dr. Umbreit received his Ph.D. in Molecular Biology/Biochemistry from Harvard and his M.D. from Tufts, completing his residency in hematology-oncology at Washington University in St. Louis. He also holds a Masters in Theology from Springhill College in Alabama.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.
Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 Susan Callahan T: 206.272.4472 F: 206.272.4434 E: media@ctiseattle.comwww.cticseattle.com/media.htm Investors Contact: Leah Grant T: 206.282.7100 F: 206.272.4434 E: invest@ctiseattle.comwww.cticseattle.com/investors.htm
Cell Therapeutics, Inc.CONTACT: media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200, orSusan Callahan, +1-206-272-4472, fax, +1-206-272-4434,media@ctiseattle.com; investors, Leah Grant, +1-206-282-7100, fax,+1-206-272-4434, invest@ctiseattle.com, all of Cell Therapeutics, Inc.
Web site: http://www.cticseattle.com/
